Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Molecular actions of smoking cessation drugs at α4β2 nicotinic receptors defined in crystal structures of a homologous binding protein.

Billen B, Spurny R, Brams M, van Elk R, Valera-Kummer S, Yakel JL, Voets T, Bertrand D, Smit AB, Ulens C.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9173-8. doi: 10.1073/pnas.1116397109. Epub 2012 May 22.

2.

Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.

Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE.

Trends Pharmacol Sci. 2007 Jul;28(7):316-25. Epub 2007 Jun 18. Review.

PMID:
17573127
3.

Efficacy and safety of varenicline for smoking cessation.

Hays JT, Ebbert JO, Sood A.

Am J Med. 2008 Apr;121(4 Suppl 1):S32-42. doi: 10.1016/j.amjmed.2008.01.017. Review.

PMID:
18342165
4.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
5.

Varenicline: progress in smoking cessation treatment.

Glover ED, Rath JM.

Expert Opin Pharmacother. 2007 Aug;8(11):1757-67. Review.

PMID:
17685891
6.
7.

Varenicline: for smoking cessation.

Rao J, Shankar PK.

Kathmandu Univ Med J (KUMJ). 2009 Apr-Jun;7(26):162-4. Review.

PMID:
20071853
8.

[Effectiveness and safety of varenicline for smoking cessation].

Christalla P, Dewenter M, El-Armouche A.

Dtsch Med Wochenschr. 2012 May;137(18):940-4. doi: 10.1055/s-0032-1304895. Epub 2012 Apr 10. Review. German.

PMID:
22492478
9.

A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation.

Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH.

Clin Pharmacokinet. 2010 Dec;49(12):799-816. doi: 10.2165/11537850-000000000-00000. Review.

PMID:
21053991
10.

The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.

Crunelle CL, Miller ML, Booij J, van den Brink W.

Eur Neuropsychopharmacol. 2010 Feb;20(2):69-79. doi: 10.1016/j.euroneuro.2009.11.001. Epub 2009 Dec 3. Review.

PMID:
19959340
11.

[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].

Kaakkola S, Tuominen R.

Duodecim. 2013;129(16):1654-60. Review. Finnish.

PMID:
24069634
12.

Structural Studies of Nicotinic Acetylcholine Receptors: Using Acetylcholine-Binding Protein as a Structural Surrogate.

Shahsavar A, Gajhede M, Kastrup JS, Balle T.

Basic Clin Pharmacol Toxicol. 2016 Jun;118(6):399-407. doi: 10.1111/bcpt.12528. Epub 2016 Jan 14. Review.

Supplemental Content

Support Center